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Background: We hypothesize that mortality risk profile of partici-
pants and nonparticipants in nonrandomized lung cancer (LC)
screening of smokers may be different.
Methods: In 1997, a population-based cohort of 5815 smokers of
Varese Province was invited to nonrandomized LC screening by
annual chest x-ray examination for 4 years. LC risk factors and
screening participation rate were recorded. Except for screening, the
whole cohort received usual care. After 9.5-year observation, we
compared mortality of participants versus nonparticipants by assess-
ing age-standardized all-cause mortality rate ratio (MRR) and dis-
ease group-specific MRR with 95% confidence intervals (95% CI).
Results: Self-selected screening participants were 21% of cohort.
Participants were younger (p  0.001), were more frequently cur-
rent smokers (p  0.019), had more pack-years of smoking (p 
0.0001), and had higher rate of LC family history (p  0.0001) and
of occupational LC risk (p  0.0001) relative to nonparticipants. In
logistic regression analysis familial LC, occupational risk and pack-
years smoked were significant predictors of participation in screen-
ing and of developing LC. Participants displayed a healthy effect, as
shown by all-cause MRR  0.67 (95% CI, 0.53–0.84), all cancers
except LC MRR  0.61 (95% CI, 0.41–0.91), cardiovascular
diseases MRR  0.38 (95% CI, 0.22–0.63), and noncancer disease
other than cardiovascular or respiratory MRR  0.57 (95% CI,
0.34–0.92). The LC mortality (MRR  1.40; 95% CI, 1.03–1.91)
was higher in participants relative to nonparticipants (p  0.031).
Conclusion: The selection effect in LC screening participants was
dual: healthy effect and higher LC mortality. In assessing the overall
effectiveness of LC screening on a population level, a higher LC
mortality risk in participants should be considered.
Key Words: Lung cancer screening, self-selection, population-
based study.
(J Thorac Oncol. 2010;5: 428–435)
Selection of volunteer participants, characterized by the“healthy effect,” has been shown in screening, and it has
raised concern about the generalizability to the population of
interest of the results of randomized cancer screenings.1–5 In
lung cancer (LC) screening of volunteers, the possible effects
of self-selection on mortality risk have been postulated6,7 but
have never been studied. Differences of mortality profile
between screening participants and nonparticipants may be
relevant for the interpretation of results of nonrandomized LC
screening on a population level.
The aim of this study was to estimate the age-standard-
ized all-cause mortality rate ratio (MRR) and the disease
group-specific MRR for participants relative to nonpartici-
pants in the PREcoce DIagnosi CAncro-early diagnosis of
cancer (PREDICA) project, a nonrandomized LC screening
study, LC screening or usual care, offered to a cohort of
smokers in Varese, Italy.
METHODS
The PREDICA Project
A pilot study of LC screening, named PREDICA
project, is ongoing since 1997 in a population-based cohort of
previously unscreened smokers of Varese, Italy.8 The screen-
ing protocol consisted of baseline two-view chest x-rays
(CXRs) and annual repeat CXR for 4 years, with 5-year
follow-up after the end of the enrollment period (January 1,
2002, to December 31, 2006). It was offered free of charge to
heavy or long-term smokers (hereafter referred to as
“PREDICA cohort”) possessing the following eligibility cri-
teria: asymptomatic cigarette smoker of more than 10 pack-
years (current smoker or ex-smoker for 10 years), resident
in Varese Province, both genders, ages 45 to 75 years, fit for
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possible thoracotomy, and without diagnosed or suspected
LC. No other exclusion criteria were used.
The PREDICA Cohort
The PREDICA cohort was recruited among all resi-
dents registered in the medical practices of 50 physicians
public general practitioners (GPs) collaborating on this
project (Appendix A). These practices, scattered over rural
and urban areas in 44 towns of the Varese Province (hereafter
referred to as “PREDICA towns,” listed in Appendix B)
included about 60,000 adults. In the whole Varese Province,
there are 805,000 inhabitants served by 597 public GPs. The
latter are paid with National Health System public funds to
provide free medical care to all the resident population. The
proportion of the Varese Province population between the age
45 and 75 years served by the 50 collaborating GPs is 8.5%.
In early 1997, the 50 GPs compiled a preliminary recruitment
list including 5925 smokers, encrypted to comply with pri-
vacy regulations, which pooled all resident smokers aged 45
to 75 years potential participants in screening. After exclud-
ing 110 noneligible candidates (unfit for surgery or with
diagnosed/suspected LC), the PREDICA cohort comprised
5815 smokers, all whites. Of the latter, we recorded age,
gender, smoker status (current/former smoker), and education
level (illiterate, elementary school, intermediate school, high
school, and university). Moreover, three LC risk factors were
recorded: number of pack-years of smoking, family history of
LC in first-degree relatives,9 and occupational exposure to
potential carcinogens.10
Until the PREDICA cohort recruitment list was com-
plete, targeted subjects were told nothing of the study. In May
1997, an invitation letter to participate in LC screening was
mailed to the 5815 cohort smokers, informing about risks and
possible benefits of screening (significantly increased resect-
ability and survivorship of screening-detected LC).
CXR Screening and Follow-Up
Individuals who accepted to be screened signed in-
formed consent and were enrolled by their GPs. For nonpar-
ticipants, the informed consent was waived. The usual stan-
dard of care provided by the National Health Service GPs was
the same in the whole PREDICA cohort, with the only
addition of annual CXR in screening participants. After
undertaking baseline CXR examination, the participants with
negative CXR reading were scheduled for subsequent annual
CXR appointments. Screening CXRs were taken in two views
(posteroanterior: 100–120 KV, 200 mA, 6–8 mAs; lateral:
120–130 KV, 200 mA, 7–9 mAs; mean total effective dose: 1.6
mGy) and were interpreted by one of three senior thoracic
radiologists. Uncertain and cancer-suspicious CXR diagnoses
were referred to our team of thoracic oncologists. All LCs
diagnosed, by screening or outside screening, were treated by
usual international criteria.11 Candidates to active LC treatment
had histologic/cytologic confirmation of diagnosis.
Enrolment and active screening period lasted 4.5 years,
from July 1, 1997, until December 31, 2001; the 5815 cohort
subjects were allocated either as participant or nonparticipant
progressively throughout that period. Follow-up was ex-
tended for 5 more years, until December 31, 2006, and the
total observation period of the cohort was 9.5 years. For all
cohort subjects, the person-years of observation were com-
puted as the time between start of study and date of study
cutoff or date of death, whichever came first, regardless of
date of allocation as participant or nonparticipant. Given the
study design, there were no dropouts: subjects who undertook
at least the baseline CXR screening by December 31, 2001,
were allocated as participants; all other subjects of the cohort
were allocated as nonparticipants.
Incidence of LC
All new LCs diagnosed in the cohort were recorded,
adopting the Varese Cancer Registry criteria,12 by linkage
with Varese Epidemiology Observatory,13 Varese Province
hospitals records and pathology records. For each new LC,
we recorded date of diagnosis, whether diagnosis was clini-
coradiologic or histologic, and histotype when available. All
LCs diagnosed during the study (at baseline or annual screen-
ing, interval cases, and cases detected outside screening) were
defined “incident” LCs.
Mortality
Deaths occurred in the cohort during the 9.5-year ob-
servation were searched by linkage with the Varese Mortality
Registry13; date and cause of death were recorded. The cohort
subjects who did not enroll in screening or who died before
end of enrolment were arbitrarily classified as nonpartici-
pants. Deaths attributable to complications of treatment of LC
were filed as deaths from LC. The Varese Mortality Registry
was accessed in 2008, completed with certificates of deaths
occurred until December 31, 2006. Death certificates were
reviewed by the mortality review committee (L.D., A.I.,
N.R., F.S., A.Po., and W.M.); only deaths definitely attrib-
uted to LC were reported as “LC deaths” in the results.
Sensitivity of death certificates in reporting LC as cause of
death was measured using the cause of death attributed by
the mortality review committee as the gold standard;
sensitivity was computed as the proportion of LC death
certificates concordant with the mortality review commit-
tee’s assessment of death attributed to LC.14 Sensitivities
of LC death certificates of participants and nonparticipants
were compared to estimate differential misclassification
bias. At study cutoff, the vital status of the PREDICA
cohort subjects were ascertained by linkage with the Lom-
bardy Health Registry of all residents in Lombardy Re-
gion,15 which allowed to trace 5730 subjects (98.5% of
cohort). For 85 subjects who left their community and
were not traceable through the Lombardy Health Registry,
investigations were done among persons’ next-of-kin and
through demographic services, without obtaining proof of
their death; therefore, these 85 subjects (1.5% of cohort)
were arbitrarily considered alive at the end of study.
To analyze mortality profile, we classified the causes of
death by disease groups, according to the International Clas-
sification of Diseases, Edition IX (ICD-IX), as follows: LC
(ICD-IX: 162.2–162.9); all cancers other than LC (ICD-IX:
140–162.0, 163–239); cardiovascular diseases (ICD-IX:
390–459); respiratory diseases (ICD-IX: 460–519); noncan-
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cer disease other than cardiovascular or respiratory (ICD-IX:
001–139, 240–389, 520–999); and all cause.
Statistical Methods
Demographic data and clinical features were reported
as frequency, percentage, mean or median, as appropriate;
95% confidence interval (95% CI) and interquartile range
were shown. Differences between participants and nonpartic-
ipants were tested by Student t test, 2 test, Fisher’s exact test,
or Mann-Whitney U test as required by type and distribution
of variables.
Age-standardized LC incidence in the PREDICA towns
general population of smokers was estimated assuming:
annual LC incidence in PREDICA towns in 1997–2006
similar to that recorded in 2000, the year for which
official data of LC incidence for Varese Province towns
are available;
proportion of LC cases occurring in smokers in PREDICA
towns was 86% of all LC cases, as documented in year
2000 in Varese Province11;
calculation of number of smokers for each age class using
gender and 10-year age class percentages of smokers as
reported by Istituto Nazionale di Statistica, Italy16;
LC incidence/1000 person-years adjusted for 2.80 male/fe-
male ratio observed in the PREDICA cohort (Table 1);
LC incidence/1000 person-years age standardized by the
direct method using as reference the European standard
population.17,18
The LC incidence in the whole PREDICA cohort was
divided by LC incidence in age-matched, gender-matched,
time period-matched, smoker status-matched (current versus
former smoker), and PREDICA towns location-matched pop-
ulation,19 yielding the LC incidence standardized rate ratio
(SRR). Multivariate logistic regression model was used to
analyze the association between screening participation or LC
incidence in participants and LC risk factors (familial LC,
occupational risk, and pack-years of smoking); odd ratios and
95% CI were estimated.
Age-standardized mortality rates/1000 person-years
were calculated by the direct method using as reference the
European standard population, the notional standard refer-
ence population defined in 1976,17,18 considering the sub-
jects’ age as of the date of study start.
All-cause and disease group-specific MRRs for screen-
ing participants and nonparticipants were computed by divid-
TABLE 1. Main Demographic Features and Lung Cancer (LC) Risk Factors of the PREDICA Cohort
Demographic Features and LC Risk Factors
PREDICA Cohort
(5815 Subjects)
Participants Subcohort
(1244 Subjects; 21%
of Cohort)
Nonparticipants Subcohort
(4571 Subjects; 79%
of Cohort) p
Mean age, yr (95% CI) 56.6 (56.4–56.8) 55.6 (55.2–56.0) 56.8 (56.6–57.1) 0.001a
Age distributions at start of project, by age ranks 0.0001b
45–54 (%) 46.1 50.3 45.0
55–64 (%) 34.3 36.0 33.9
65–74 (%) 19.5 13.7 21.1
Male (%) 73.7 74.6 73.5 0.420b
Mean age in males, yr (95% CI) 56.9 (56.7–57.2) 55.9 (55.5–56.4) 57.2 (56.9–57.5) 0.0001a
Mean age in females, yr (95% CI) 55.6 (55.2–56.0) 54.6 (53.8–55.4) 55.8 (55.3–56.3) 0.018a
Education levelc 0.219b
Subjects with intermediate school or lower
education, n (%)
1697 (80.9) 422 (82.7) 1275 (80.3)
Subjects with high school or higher education,
n (%)
401 (19.1) 88 (17.3) 313 (19.7)
Smoker statusd 0.019b
Current smoker, n (%) 4208 (76.3) 865 (79.1) 3343 (75.6)
Former smoker, n (%) 1310 (23.7) 228 (20.9) 1082 (24.4)
Pack-yr smokede median (IQR) 32.8 (22.8–46.0) 35.4 (26.6–49.0) 31.6 (21.6–45.0) 0.0001f
Subjects with family history of LCg, n (%) 157 (5.92) 95 (8.95) 62 (3.90) 0.0001b
Subjects with occupational risk of LCh, n (%) 817 (28.7) 474 (43.5) 343 (19.5) 0.0001b
Person-yr of observation 51 606.9 11 315.1 40 291.8 —
Mean person-yr of observation (95% CI) 8.87 (8.83–8.91) 9.10 (9.02–9.17) 8.81 (8.76–8.87) 0.0001a
Comparison of CXR screening participants vs. nonparticipants. Mean values are presented with 95% confidence intervals (95% CI). The data of pack-yr smoked, family history
of lung cancer and occupational risk were all exactly available for 1779/5815 subjects or 30.6% of the PREDICA cohort.
a Student t test.
b 2 test.
c Available in 2098 subjects (36.1% of cohort).
d Available in 5518 subjects (94.9% of cohort).
e Available in 3824 subjects (65.8% of cohort).
f Mann-Whitney U test.
g Available in 2650 subjects (45.6% of cohort).
h Available in 2845 subjects (48.9% of cohort).
IQR, interquartile range; CXR, chest x-ray.
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ing age-standardized mortality rate of participants by age-
standardized mortality rate of nonparticipants. The Cox
regression model was also used to estimate the hazard risk of
death in participants versus nonparticipants.
Poisson distribution was assumed to estimate the dif-
ference in LC incidence and in disease group-specific or
all-cause mortality rate between participants and nonpartici-
pants, with 95% CI. Differences with p  0.05 were consid-
ered significant. Analysis was performed at the Department
of Medicine and Public Health, University of Verona (A.Po.,
W.M.), using Stata software (Stata Corporation, College
Station, TX). This study was approved by the Varese Hospital
and Health District Ethics Committee.
RESULTS
Participation Rate and Person-Years of
Observation
Participants in screening were 1244 of 5815 invited
subjects (21%), hereafter referred to as participants subcohort
(Table 1). The median number of screening rounds under-
went by each subject, including baseline examination, was
three instead of the five expected, despite reminder calls.
There were 278 other subjects (5% of cohort) who signed
consent for screening but did not participate. The remaining
4293 subjects (74% of cohort) did not accept the invitation to
participate in screening. Cumulatively 4571 subjects (79% of
cohort) did not participate; hereafter, they are referred to as
nonparticipants subcohort. In the whole cohort, the cumula-
tive person-years of observation were 51 606.9.
Risk Factors
Demographic and risk features are given in Table 1.
The pattern of data missingness is reported in Table 1. The
data of three LC risk factors considered for regression anal-
ysis (pack-years, family history of LC, and occupational risk)
were all exactly present in 1779 of 5815 subjects or 30.6% of
the whole PREDICA cohort.
Participants were younger than nonparticipants (p 
0.001), and age distributions within subcohorts were dif-
ferent (p  0.0001). The subcohorts displayed similar
gender ratio (p  0.420) and education level (p  0.219).
Participants featured more pack-years of smoking (p 
0.0001) and higher prevalence of current smokers (p 
0.019), family history of LC (p  0.0001), and occupa-
tional risk (p  0.0001).
Incidence of LC
During the 9.5-year observation period, 245 diagnoses
of LC were made (67 participants, 178 nonparticipants). The
proportion of histology/cytology-confirmed LC diagnoses
was higher in participants than in nonparticipants (p 0.028;
Table 2). The proportion of LC diagnoses that were histolog-
ically confirmed in nonparticipants was essentially identical
to that observed in the year 2000 in the Varese general
population (82%).11 Distribution of histologic types was sim-
ilar in the subcohorts (p  0.573; Table 2).
The age-standardized LC incidence/1000 person-years
in participants was 7.88 (95% CI, 5.52–10.24), significantly
higher (p  0.001) than in nonparticipants (4.65 [95% CI,
3.94–5.37]). Age-standardized LC incidence observed in the
whole PREDICA cohort was 5.15 (95% CI, 4.47–5.84)/1000
person-years, while the LC incidence expected in the
PREDICA towns-matched population was 4.81 (95% CI,
4.06–5.68)/1000 person-years. The PREDICA cohort LC
incidence SRR was 1.07 (95% CI, 0.87–1.31).
Mortality
During the study period, 866 subjects died (118 partic-
ipants, 748 nonparticipants). Crude mortality rates for all
causes, for LC, and for other disease groups considered are
presented in Table 3.
Age-standardized MRRs are presented in Table 4. Par-
ticipants had lower age-standardized all-cause mortality
(MRR, 0.67; p  0.0001) and a pattern of lower age-
standardized mortality for all-disease groups considered ex-
cept LC, relative to nonparticipants. In fact, as shown in
Table 4, participants had lower mortality for all cancers other
than LC (MRR, 0.61; p  0.003), cardiovascular diseases
(MRR, 0.38; p  0.0001), and noncancer disease other than
cardiovascular or respiratory (MRR, 0.57; p  0.019), rela-
tive to nonparticipants. The lower mortality from respiratory
diseases of participants was borderline significant (MRR,
0.51; p  0.068). These results suggest that participants
self-selected as healthier subjects.
As an alternative method to direct standardization, to
control the age-related confounding, we used the Cox regres-
sion model; the hazard risk of death in participants versus
nonparticipants was 0.66 (95% CI, 0.54–0.80), essentially
identical to the 0.67 all-cause MRR obtained by direct age
standardization.
During the study period, 179 subjects (40 participants,
139 nonparticipants) died of LC. Because of exclusion from
TABLE 2. Histopathologic Lung Cancer Diagnoses in the
PREDICA Cohort
PREDICA
Cohort
(5815
Subjects)
Participants
Subcohort
(1244
Subjects)
Nonparticipants
Subcohort
(4571
Subjects) p
No. diagnosed
lung cancersa
(% subjects)
245 (4.2) 67 (5.4) 178 (3.9)
Histologically
confirmed cases,
n (%)
211 (86) 63 (94) 148 (83) 0.028b
Squamous cell
carcinoma, n (%)
81 (38) 27 (43) 54 (37) 0.573c
Adenocarcinoma,
n (%)
69 (33) 18 (29) 51 (34)
Small cell
carcinoma, n (%)
29 (14) 11 (17) 18 (12)
Undetermined
NSCLC, n (%)
32 (15) 7 (11) 25 (17)
Comparison of CXR screening participants vs. nonparticipants.
a Lung cancer: ICD-IX 162.2–162.9.
b Fisher’s exact test.
c 2 test.
NSCLC, nonsmall cell lung cancer; CXR, chest x-ray.
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enrolment of individuals with ascertained or suspected LC, in
the first year of study, only one LC death (participant) was
recorded in the cohort. Sensitivity of LC death certificates
was high: 164 of 179 (91.6%) LC death certificates were
confirmed by the mortality review committee. Sensitivity of
LC death certificates was similar in participants and nonpar-
ticipants (92.5% versus 91.4%; p  0.819). Importantly,
participants had higher LC mortality than nonparticipants
(MRR, 1.40; p  0.031).
A group of PREDICA cohort subjects (n  1779;
30.6% of cohort) with complete information on LC risk
factors was available for further analysis. Preliminary evalu-
ation showed that the complete information group (30.6% of
cohort) and the incomplete information group (69.4% of
cohort) had similar mean age (participants, 55.4 versus 55.7
years, respectively; p  0.578; nonparticipants, 56.7 versus
57.2 years, respectively; p  0.112), gender distribution
(participants, 73.8% versus 75.0% male, respectively; p 
0.628; nonparticipants, 73.7% versus 72.6% male, respec-
tively; p  0.112) and age-standardized all-cause mortality
rate/1000 years (participants, 13.78 versus 15.67, respec-
tively; p 0.418; nonparticipants, 21.21 versus 25.21 respec-
tively; p  0.103). To analyze the association between
screening participation or LC diagnosis and LC risk factors,
the multivariate logistic regression model was performed
only on the complete information group (Table 5).
Participation in screening significantly correlated with
familial LC (p  0.001), occupational risk (p  0.0001), and
pack-years smoked (p  0.002). Incident LC also correlated
with these predictors, although occupational LC risk did not
reach statistical significance (p  0.089; Table 5).
DISCUSSION
In the PREDICA LC screening, the participation rate
was low (21%), similar to the 20 to 33% observed in Japanese
population LC screenings.20,21 A relevant question is to what
extent the low attendance in LC screening and the volunteer
effect impact on LC mortality in population-based LC screen-
ing. The features of our cohort study, population-based,
nonrandomized, and with essentially complete (98.5%) long-
term follow-up allow the evaluation of the effects of self-
selection on the mortality profile of LC screening participants. In
the PREDICA cohort, we observed a volunteer effect character-
TABLE 3. Crude Mortality Rates (per 1000 Person-yr) with 95% Confidence Intervals (95% CI) by
Causes in the PREDICA Cohort
Cause of Death
PREDICA Cohort
(5815 Subjects)
Participants Subcohort
(1244 Subjects)
Nonparticipants Subcohort
(4571 Subjects) pa
Lung cancer (LC)b 0.892
n 179 40 139
Rate 3.47 3.53 3.45
95% CI 2.97–4.02 2.52–4.81 2.90–4.07
All cancers other than LC 0.001
n 269 36 233
Rate 5.21 3.18 5.78
95% CI 4.61–5.87 2.23–4.40 5.06–6.58
Cardiovascular diseasesc 0.0001
n 245 22 223
Rate 4.75 1.94 5.53
95% CI 4.17–5.38 1.22–2.94 4.83–6.31
Respiratory diseasesd 0.048
n 55 6 49
Rate 1.06 0.53 1.22
95% CI 0.80–1.39 0.18–1.15 0.90–1.61
Noncancer disease other than
cardiovascular or respiratory
0.008
n 118 14 104
Rate 2.29 1.24 2.58
95% CI 1.89–2.74 0.68–2.08 2.11–3.13
All cause 0.0001
n 866 118 748
Rate 16.78 10.43 18.56
95% CI 15.68–17.94 9.63–12.49 17.26–19.94
Comparison of CXR screening participants vs. nonparticipants.
a 2 test.
b Lung cancer: ICD-IX 162.2–162.9.
c Cardiovascular diseases: ICD-IX 390–459.
d Respiratory diseases: ICD-IX 460–519.
CXR, chest x-ray.
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ized by significantly lower all-cause mortality and by signifi-
cantly lower mortality for several disease groups, except LC.
After age standardization, the all-cause mortality in participants
remained significantly lower, indicating that self-selection had a
healthy effect independent of age.
Participants had significantly higher age-standardized
LC incidence (p  0.001) and LC mortality (LC MRR, 1.40;
p  0.031) relative to nonparticipants. The higher LC inci-
dence in participants was expected, likely because of higher
prevalence of LC risk factors observed and because of some
LC overdiagnosis from CXR screening.22 Only 30.6% of the
PREDICA cohort featured complete LC risk information;
therefore, the significantly higher familial LC, occupational
risk, and pack-years smoked estimated among participants
should be cautiously interpreted, although the complete in-
formation group and the rest of the cohort were similar for
age, gender distribution, and age-standardized all-cause mor-
tality rate. Similarly, the logistic regression analysis, which
suggested that the three LC risk factors were predictors of
participation in screening and of developing incident LC,
should be interpreted cautiously.
The distribution of LC histologic types was similar in
the two subcohorts and similar to that of LCs diagnosed in the
Varese smokers population in 2000.11 The 40% higher LC
mortality observed in participants is a large difference, for
which several possible causes are worthy of consideration. It
is unrealistic to postulate a lethal effect of the screening
CXRs, an effect that does not occur in clinical practice.
Enrolment of self-selected symptomatic smokers as
screenees might cause an overestimation of LC mortality; the
excess of LC deaths in participants, however, cannot be
justified in this way, because during the first year of study,
only one subject died of LC in the participants subcohort.
Death certificate errors and sticky-diagnosis bias might also
determine overrepresented LC mortality in participants by
selective misclassification. Histologic confirmation rate of
LCs diagnosed in participants in our study was 11% higher
than in nonparticipants, a modest difference that would ac-
count for only slight overrepresentation of participants’ LC
mortality. Sensitivity of LC death certificates was high and
similar in participants and nonparticipants (92.5 and 91.4%,
respectively), suggesting that selective misclassification did
not contribute appreciably to the 1.40 LC MRR recorded. A
modest misclassification rate of deaths was observed also in
the Mayo LC screening project14 and in population-based
mammographic screening.23
Selection bias seems to be the main cause of the mortality
difference between participants and nonparticipants in the
PREDICA LC screening project. We hypothesize that, in our
study, the decision of smokers to attend screening was influ-
enced by their awareness of being at higher LC risk. This
hypothesis is supported by a recent study showing that smokers
who perceived themselves at higher risk were the most inter-
ested in screening.24 Current smokers and heavy smokers
perceived their LC risk as higher than former smokers and
light smokers; moreover, smokers with a family history of LC
perceived a higher LC risk.24 Also, in the setting of colorectal
screening, a family history of colorectal cancer correlated
with increased screening attendance.25 In the PREDICA co-
hort, 100% of subjects were aware of their smoking-related
TABLE 4. Cumulative Age-Standardized Mortality Rates (per 1000 Person-yr) with 95% Confidence Intervals (95% CI) by
Causes in the PREDICA Cohort
Cause of Death
PREDICA Cohort
(5815 Subjects)
Participants Subcohort
(1244 Subjects)
Nonparticipants Subcohort
(4571 Subjects) MRR pa
Lung cancer (LC)b (95% CI) 3.71 (3.14–4.23) 4.95 (3.10–6.86) 3.53 (2.93–4.15) 1.40 (1.03–1.91) 0.031
All cancers other than LC (95% CI) 5.23 (4.62–5.95) 3.48 (2.17–4.78) 5.72 (4.95–6.48) 0.61 (0.41–0.91) 0.003
Cardiovascular diseasesc (95% CI) 5.37 (4.65–6.08) 2.25 (1.11–3.34) 5.99 (5.17–6.81) 0.38 (0.22–0.63) 0.0001
Respiratory diseasesd (95% CI) 1.29 (0.93–1.66) 0.71 (0.08–1.42) 1.39 (0.98–1.80) 0.51 (0.24–1.06) 0.068
Noncancer disease other than
cardiovascular or respiratory
(95% CI)
2.63 (2.13–3.13) 1.63 (0.58–2.68) 2.85 (2.27–3.42) 0.57 (0.34–0.92) 0.019
All cause (95% CI) 18.29 (17.00–19.58) 13.01 (10.14–15.89) 19.48 (18.03–20.94) 0.67 (0.53–0.84) 0.0001
Comparison of CXR screening participants vs. nonparticipants. Mortality rate ratio (MRR): age-standardized cause-specific mortality rate in participants/age-standardized
cause-specific mortality rate in nonparticipants.
a p value testing MRR  1.
b Lung cancer: ICD-IX 162.2–162.9.
c Cardiovascular diseases: ICD-IX 390–459.
d Respiratory diseases: ICD-IX 460–519.
CXR, chest x-ray.
TABLE 5. Predictors of Being Participant in Lung Cancer
(LC) Screening and of Incident LC Diagnosis
Outcome Predictor OR (95% CI) p
Participant in LC
screening
Familial LC 1.99 (1.31–3.01) 0.001
Occupational LC
risk
4.42 (3.52–5.54) 0.0001
Pack-yr unit
increment
1.01 (1.00–1.01) 0.002
Incident LC
diagnosis
Familial LC 2.02 (1.11–3.68) 0.021
Occupational LC
risk
1.38 (0.95–1.99) 0.089
Pack-yr unit
increment
1.02 (1.01–1.03) 0.0001
The analysis was performed in 1779 subjects (30.6% of the PREDICA cohort) for
whom all predictors were available. Odds ratios and 95% confidence interval (OR, 95%
CI) are shown.
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LC risk, illustrated in the screening invitation letter. More-
over, in smokers with a family history of LC or with occu-
pational/environmental exposure risk, increased awareness of
LC risk might be prompted also by family doctor, family
members, or peers. It is not surprising that a low interest in
screening was found in a survey study of light smokers
(median: 10 pack-years), with only 21% of the group warned
about LC risk.26
Our study has limitations. No data on the income level
were available for the cohort subjects; we used the education
level as surrogate measure of income level. The finding of a
slightly lower education level among the participants in our
screening is unusual, compared with most screening studies.
The difference could be explained by a higher participation in
LC screening of subjects with occupational risk and with
lower education level, as suggested by the greater proportion
of subject with occupational risk in lower versus higher
education level that we observed (39.5% versus 20.0%,
respectively; p  0.001).
Another limitation of this study is the long duration of
enrolment, lasting 4.5 years, a period similar to that of the
Mayo Lung Project enrolment.27 In the real world of cancer
screening, when thousands of candidates are involved, enrol-
ment over long time is inevitable, and in our study, it might
have slightly inflated all-cause mortality of nonparticipants.
Compliance with annual screening schedule was sub-
optimal (three CXR examinations per participant), possibly
compromising the effectiveness of LC screening; however we
did not address the issue of low compliance with CXR exams,
because the aim of this report was to estimate self-selection,
not to assess screening effectiveness.
Two important questions are whether the PREDICA
cohort was complete of all smokers eligible for screening
resident in the public GP practices considered and whether it
represented the Varese smokers population. As to the first
question, the preliminary recruitment list of all smokers aged
45 to 75 years included 5925 subjects, i.e., 20.6% of target
age-group residents in the 50 GP practices; this proportion of
smokers is essentially identical to the 21% of smokers in the
same age-group Lombardy general population, as surveyed in
2000.16 Moreover, recruited smokers were resident in 44
towns scattered in Varese Province, and the LC incidence
SRR of the PREDICA cohort was 1.07, suggesting that the
PREDICA cohort LC incidence represented that of Varese
smokers.
In conclusion, this population-based study of smokers
shows that participation in CXR screening is associated with
a healthy effect and a higher LC mortality risk. Moreover, our
results suggest that the increased LC mortality in screening
participants could be because of self-selection of subjects
with higher LC risk. To assess the effectiveness of a CXR
screening intervention in smokers on a population level, the
possibility of higher LC mortality risk in self-selected partic-
ipants must be considered. If subjects at risk were overrep-
resented among screening participants, effectiveness of
screening on a population level could theoretically increase;
the evaluation of the impact of self-selection on population-
based LC screening effectiveness, however, is beyond the
purpose of this study and requires further investigations.
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APPENDIX A
List of 50 General Practitioners of the Italian National
Health System working in the Varese Province who collab-
orated on the PREDICA project: Adreani L, Agosti C, An-
gelini M, Baj A, Bellingreri V, Borgese S, Bossi P, Brando-
lino N, Castelli N, Castiglioni D, Cocquio F, Colmegna A,
Colombo G, Cordani A, Cova G, Damiani M, Daverio C,
Diana R, Dozio F, Gandini T, Giacomino M, Giuliani C,
Incremona M, Ligabo` M, Lunardon M, Magnaghi F, Ma-
rangoni L, Marciano` M, Mazza G, Morenghi R, Nicora F,
Pala R, Pasquali C, Pisani S, Pisciotta M, Pizzi M, Rizzuto G,
Roberto V, Rossi N, Sassi G, Scienza G, Sinapi D, Tamborini
M, Testorelli M, Tonello E, Trotta L, Valente A, Vigoni V,
Zanzi C, and Zecchini D.
APPENDIX B
List of “PREDICA towns” in the Varese Province:
Albizzate, Arcisate, Azzate, Besano, Besozzo, Bisuschio,
Bodio Lomnago, Brezzo di Bedero, Brissago Valtravaglia,
Brunello, Buguggiate, Cantello, Caronno Varesino, Cassano
Magnano, Cittiglio, Clivio, Cuasso al Monte, Cugliate Fabi-
asco, Cunardo, Cuveglio, Daverio, Gallarate, Galliate Lom-
bardo, Gavirate, Gazzada Schianno, Germignaga, Induno
Olona, Laveno Mombello, Lonate Pozzolo, Luino, Malnate,
Marchirolo, Mesenzana, Morazzone, Mornago, Oggiona con
Santo Stefano, Porto Ceresio, Rancio Valcuvia, Saltrio, Sa-
marate, Solbiate Arno, Valganna, Varese, and Viggiu`.
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